Description

3-(4-Bromo-3-[1,3]Dioxolan-2-Yl-Benzyl)-2-Butyl-1,3-Diaza-Spiro[4.4]Non-1-En-4-One (Wxc01975) is a high-purity, advanced pharmaceutical intermediate characterized by its complex spirocyclic and diaza-enone structure. This compound is critical for research and development in medicinal chemistry, particularly in the synthesis of novel active pharmaceutical ingredients (APIs). It is primarily utilized by pharmaceutical R&D laboratories, fine chemical manufacturers, and academic institutions engaged in the development of new therapeutic agents.

Application

• Pharmaceutical Intermediate: A key building block in the multi-step synthesis of complex drug candidates, especially those targeting central nervous system (CNS) disorders.
• Medicinal Chemistry Research: Serves as a versatile scaffold for structure-activity relationship (SAR) studies and lead optimization in drug discovery programs.
• Organic Synthesis: Used in advanced organic transformations, including spirocyclization and heterocycle formation, to create novel chemical entities.
• Contract Research & Manufacturing (CRAM): Supplied to CROs and CDMOs for custom synthesis projects requiring high-fidelity, specialized intermediates.
• Academic Research: Employed in university laboratories for studying novel synthetic methodologies and reaction mechanisms involving complex heterocycles.

Basic Information

Product Name	3-(4-Bromo-3-[1,3]Dioxolan-2-Yl-Benzyl)-2-Butyl-1,3-Diaza-Spiro[4.4]Non-1-En-4-One (Wxc01975)
CAS No.	254744-55-3
Molecular Formula	C21H27BrN2O3
Molecular Weight	435.36 g/mol
Synonyms	WXC-01975; WXC01975; 2-Butyl-3-[(4-bromo-3-(1,3-dioxolan-2-yl)phenyl)methyl]-1,3-diazaspiro[4.4]non-1-en-4-one; 1,3-Diaza-spiro[4.4]non-1-ene-4-one, 3-[(4-bromo-3-(1,3-dioxolan-2-yl)phenyl)methyl]-2-butyl-; 254744-55-3; 3-(4-Bromo-3-(1,3-dioxolan-2-yl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
EINECS	Contact for details

Quality Control

Our 3-(4-Bromo-3-[1,3]Dioxolan-2-Yl-Benzyl)-2-Butyl-1,3-Diaza-Spiro[4.4]Non-1-En-4-One (Wxc01975) is manufactured under strict quality management systems to ensure batch-to-batch consistency and high purity. Each lot undergoes comprehensive analytical testing, including HPLC, NMR, and MS, to confirm identity and purity. A detailed Certificate of Analysis (COA) is provided with every shipment, documenting all critical quality attributes. We support cGMP compliance for pharmaceutical applications, and specifications can be aligned with client requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (15-25°C). The compound is moisture-sensitive; keep the original container tightly sealed under an inert atmosphere (e.g., nitrogen or argon) for long-term storage to prevent degradation. Keep away from heat and incompatible materials.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (NMR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.